Transpedal vs. femoral access for peripheral arterial interventions-A single center experience.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 Jun 2019
Historique:
received: 24 06 2018
revised: 29 01 2019
accepted: 16 03 2019
pubmed: 29 3 2019
medline: 7 7 2020
entrez: 29 3 2019
Statut: ppublish

Résumé

To compare the transpedal approach to established femoral approach for endovascular treatment of infrainguinal peripheral arterial disease. Endovascular treatment of infrainguinal peripheral arterial disease is on the rise. Femoral approach is widely used but has significant complications. Recently the primary transpedal approach has been described for endovascular interventions. We hypothesized that transpedal approach could reduce access site related complications. We compared the two approaches in a retrospective cross-sectional study at a single center. We analyzed demographics, procedural parameters, and complications in patients who underwent a primary transpedal approach for infrainguinal intervention and compared to patients with a traditional femoral approach in our outpatient based endovascular lab. The success rate for access was lower in transpedal group compared to femoral (94% vs. 100%, p = .0002). The contrast dose (44 ± 11 mL vs. 68 ± 13 mL, p < .0001), radiation dose (25 mGy [16-43] vs. 48 mGy [36-67], p < .0001) and fluoroscopy time (5.48 min [3.48-11.71] vs. 9.35 min [6.63-14.11], p < .0001) were significantly lower in transpedal group. The transpedal approach for infrainguinal revascularization appears to be a reasonable primary approach with high success and low complication rate with significant reduction in radiation and contrast dose. These findings should be further studied in a randomized controlled trial.

Sections du résumé

OBJECTIVE OBJECTIVE
To compare the transpedal approach to established femoral approach for endovascular treatment of infrainguinal peripheral arterial disease.
BACKGROUND BACKGROUND
Endovascular treatment of infrainguinal peripheral arterial disease is on the rise. Femoral approach is widely used but has significant complications. Recently the primary transpedal approach has been described for endovascular interventions. We hypothesized that transpedal approach could reduce access site related complications. We compared the two approaches in a retrospective cross-sectional study at a single center.
METHODS METHODS
We analyzed demographics, procedural parameters, and complications in patients who underwent a primary transpedal approach for infrainguinal intervention and compared to patients with a traditional femoral approach in our outpatient based endovascular lab.
RESULTS RESULTS
The success rate for access was lower in transpedal group compared to femoral (94% vs. 100%, p = .0002). The contrast dose (44 ± 11 mL vs. 68 ± 13 mL, p < .0001), radiation dose (25 mGy [16-43] vs. 48 mGy [36-67], p < .0001) and fluoroscopy time (5.48 min [3.48-11.71] vs. 9.35 min [6.63-14.11], p < .0001) were significantly lower in transpedal group.
CONCLUSION CONCLUSIONS
The transpedal approach for infrainguinal revascularization appears to be a reasonable primary approach with high success and low complication rate with significant reduction in radiation and contrast dose. These findings should be further studied in a randomized controlled trial.

Identifiants

pubmed: 30920716
doi: 10.1002/ccd.28209
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1311-1314

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Sooraj M Shah (SM)

Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Anna Bortnick (A)

Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Olivier F Bertrand (OF)

Department of Medicine, Division of Cardiology, Quebec Heart-Lung Institute, Quebec, QC, Canada.

Olivier Costerousse (O)

Department of Medicine, Division of Cardiology, Quebec Heart-Lung Institute, Quebec, QC, Canada.

Wah W Htun (WW)

Department of Medicine, Division of Cardiology, Mount Sinai Beth Israel, New York, New York.

Tak W Kwan (TW)

Department of Medicine, Division of Cardiology, Mount Sinai Beth Israel, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH